0000895345-11-000146.txt : 20110428 0000895345-11-000146.hdr.sgml : 20110428 20110428114801 ACCESSION NUMBER: 0000895345-11-000146 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20110428 DATE AS OF CHANGE: 20110428 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INSPIRE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001040416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043209022 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60379 FILM NUMBER: 11786526 BUSINESS ADDRESS: STREET 1: 4222 EMPEROR BLVD STE 200 CITY: DURHAM STATE: NC ZIP: 27703-8466 BUSINESS PHONE: 9199419777 MAIL ADDRESS: STREET 1: 4222 EMPEROR BLVD STREET 2: STE 200 CITY: DURHAM STATE: NC ZIP: 27703-8466 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Monarch Transaction Corp. CENTRAL INDEX KEY: 0001517906 IRS NUMBER: 451540007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: ONE MERCK DRIVE STREET 2: P.O. BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889 BUSINESS PHONE: (908) 423-1000 MAIL ADDRESS: STREET 1: ONE MERCK DRIVE STREET 2: P.O. BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889 SC TO-T/A 1 dsamend-inspire_monarch.htm dsamend-inspire_monarch.htm
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE TO

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
(Amendment No. 1)

INSPIRE PHARMACEUTICALS, INC.
(Name of Subject Company (Issuer))

MONARCH TRANSACTION CORP.
MERCK & CO., INC.
(Name of Filing Persons (Offerors))

COMMON STOCK, PAR VALUE $.001 PER SHARE
(INCLUDING ASSOCIATED PREFERRED STOCK PURCHASE RIGHTS)
(Title of Class of Securities)

457733103
(CUSIP Number of Class of Securities)
 
Richard N. Kender
Senior Vice President, Business Development and Corporate Licensing
Merck & Co., Inc.
One Merck Drive, PO Box 100
Whitehouse Station, NJ 08889-0100
(908) 423-1000
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications on Behalf of Filing Persons)

Copies to:
David N. Shine, Esq.
Fried, Frank, Harris, Shriver & Jacobson LLP
One New York Plaza
New York, New York 10004
(212) 859-8000

 
CALCULATION OF FILING FEE
 
Transaction Valuation *
  
Amount of Filing Fee**
$481,393,285
  
$55,889.76

*
Estimated for purposes of calculating the filing fee only. This amount is based on the offer to purchase at a purchase price of $5.00 cash per share (i) all 83,292,192 outstanding shares of common stock of Inspire; (ii) all restricted stock units with respect to 1,665,719 shares of common stock of Inspire; and (iii) all outstanding options respect to 11,320,746 shares of common stock of Inspire, in each case as of April 1, 2011, the most recent practicable date.
**
The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #5 for fiscal year 2011, issued December 22, 2010, by multiplying the transaction valuation by 0.00011610.
 
x
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 
  Amount Previously Paid: $55,889.76 Filing Party: Monarch Transaction Corp.
  Form or Registration No.: Schedule TO-T  Date Filed:   April 15, 2011
                                                                                                                                                                                                                                               
¨           Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes to designate any transactions to which this statement relates:

x
third-party tender offer subject to Rule 14d-1
o
going-private transaction subject to Rule  13e-3
o
issuer tender offer subject to Rule 13e-4
 
o            amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer. ¨

 
 
 
 
 
This Amendment No. 1 to the Tender Offer Statement on Schedule TO (this “Amendment”) filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2011, amends and supplements the Tender Offer Statement on Schedule TO filed on April 15, 2011 (as further amended and supplemented, the “Schedule TO”), relating to the offer by Offeror (as defined below) to purchase all of the outstanding shares of common stock, par value $0.001 per share (together with the associated preferred stock purchase rights, each a “Share” and collectively, the “Shares”), of Inspire Pharmaceuticals, Inc., a Delaware corporation (“Inspire”), at a purchase price of $5.00 per Share, net to the seller in cash, without interest thereon and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated April 15, 2011 (which, together with this Amendment and any previous or future amendments and supplements thereto, collectively constitute the “Offer to Purchase”), and in the related letter of transmittal (the “Letter of Transmittal”), copies of which are attached to the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, collectively constitute the “Offer”). The Schedule TO (including the Offer to Purchase) filed with the SEC by Monarch Transaction Corp., a Delaware corporation (“Offeror”) and Merck & Co., Inc., a corporation formed under the laws of New Jersey (“Merck”), on April 15, 2011, as amended by this Amendment and the Solicitation/Recommendation Statement on Schedule 14D−9 filed with the SEC by Inspire on April 15, 2011, as amended or supplemented from time to time, contain important information about the Offer, all of which should be read carefully by Inspire stockholders before any decision is made with respect to the Offer. The Offer is made pursuant to the Agreement and Plan of Merger, dated as of April 5, 2011, by and among Merck, Offeror and Inspire.

Documentation relating to the Offer has been mailed to Inspire stockholders and may be obtained at no charge at the website maintained by the SEC at www.sec.gov and may also be obtained at no charge by directing a request by mail to Georgeson Inc., the Information Agent for the Offer, at 199 Water Street, 26th Floor, New York, NY 10038, or by calling toll−free at (800) 279-6913.

All information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated by reference herein in response to Items 1 through 9 and Item 11 of the Schedule TO, and is supplemented by the information specifically provided in this Amendment. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Offer to Purchase or in the Schedule TO.

Item 11.

The Offer to Purchase and Item 11(a) of the Schedule TO, to the extent Item 11 incorporates by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as set forth below.

Section 16 — “Certain Legal Matters; Regulatory Approvals” of the Offer to Purchase is hereby amended and supplemented by adding the following text at the end of the second paragraph of the sub-section captioned “U.S. Antitrust”:

“The waiting period under the HSR Act applicable to the Offer and the Merger expired effective 11:59 p.m. on April 27, 2011.  As a result, the condition of the Offer related to the early expiration or termination of the waiting period under the HSR Act has been satisfied.”

Section 16 — “Certain Legal Matters; Regulatory Approvals” of the Offer to Purchase is hereby amended and supplemented by adding the following as a new paragraph to the end of the sub-section captioned “Legal Proceedings”:

“On April 15, 2011, a purported class action lawsuit was filed against Inspire, the Inspire Board, Merck and Offeror in the Court of Chancery of the State of Delaware, under the caption Maz Aiyub, individually and on behalf of all others similarly situated v. George Abercrombie, et al., Case No. 6381.  The plaintiffs in this case purport to sue on behalf of a class of stockholders of Inspire, and allege that members of the Inspire Board breached their fiduciary duties to the members of the class by, among other things, failing to maximize shareholder value in connection with the sale of Inspire to Merck. The complaint also alleges that Inspire, Merck, and Offeror aided and abetted the Inspire Board in the Inspire Board’s purported breach of their fiduciary duties. The relief sought includes, among other things, an injunction preventing the proposed sale of Inspire and tender offer, rescission, to the extent already performed, of the Merger Agreement, or granting plaintiffs rescissory damages, and reimbursement of plaintiffs’ costs, including reasonable attorney and expert fees.

On April 15, 2011, a purported class action lawsuit was filed against Inspire, the Inspire Board, Merck and Offeror in the Court of Chancery of the State of Delaware, under the caption Pradeep Bheda, individually and on behalf of all others similarly situated v. George Abercrombie, et al., Case No. 6382. The plaintiffs in this case purport to sue on behalf of a class of stockholders of Inspire, and allege that members of the Inspire Board breached their fiduciary duties to the members of the class by, among other things, failing to maximize shareholder value in connection with the sale of Inspire to Merck. The complaint also alleges that Inspire, Merck, and Offeror aided and abetted the Inspire Board in the Inspire Board’s purported breach of their fiduciary duties. The relief sought includes, among other things, an injunction preventing the proposed sale of Inspire and tender offer, rescission, to the extent already performed, of the Merger Agreement, or granting plaintiffs rescissory damages,  and reimbursement of plaintiffs’ costs, including reasonable attorney and expert fees.

On April 20, 2011, plaintiffs amended the complaint originally filed on April 14, 2011, related to a purported class action lawsuit was filed against Inspire, the Inspire Board, Merck and Offeror in the Court of Chancery of the State of Delaware, under the caption Steve Dougherty, On Behalf of Himself and All Others Similarly Situated v. Inspire Pharmaceuticals, Inc., et al., Case No. 6378.  The plaintiffs in this case purport to sue on behalf of a class of stockholders of Inspire, and allege that members of the Inspire Board breached their fiduciary duties to the members of the class by, among other things, failing to maximize shareholder value in connection with the sale of Inspire to Merck.  In addition, the amended complaint alleges that the Board breached its fiduciary duty to disclose material information.  The complaint also alleges that Inspire, Merck, and Offeror aided and abetted the Inspire Board in the Inspire Board’s purported breach of their fiduciary duties.  The relief sought includes, among other things, an injunction preventing the proposed sale of Inspire and tender offer, rescission, to the extent already performed, of the Merger Agreement, or granting plaintiffs rescissory damages, and reimbursement of plaintiffs’ costs, including reasonable attorney and expert fees.

On April 21, 2011, a purported class action lawsuit was filed against Inspire, the Inspire Board, Merck and Offeror in the Court of Chancery of the State of Delaware, under the caption Raymond Chan, on behalf of himself and all others similarly situated v. Inspire Pharmaceuticals, Inc., et al., Case No. 6401. The plaintiffs in this case purport to sue on behalf of a class of stockholders of Inspire, and allege that members of the Inspire Board breached their fiduciary duties to the members of the class by, among other things, failing to maximize shareholder value in connection with the sale of Inspire to Merck. The complaint also alleges that Inspire, Merck, and Offeror aided and abetted the Inspire Board in the Inspire Board’s purported breach of their fiduciary duties. The relief sought includes, among other things, an injunction preventing the proposed sale of Inspire and tender offer, rescission, to the extent already performed, of the Merger Agreement, or granting plaintiffs rescissory damages, and reimbursement of plaintiffs’ costs, including reasonable attorney and expert fees.

On April 25, 2011, Vice Chancellor Parsons of the Court of Chancery of the State of Delaware signed an order consolidating all of the Delaware actions (with the exception of the Luttenberger action, which was filed on April 11, 2011, but which plaintiffs moved to voluntarily dismiss on April 14, 2011) into one action called In re Inspire Shareholders Litig., C.A. 6328-VCP.

 On April 19, 2011, plaintiffs amended the complaint originally filed on April 14, 2011, relating to a purported class action lawsuit filed against Inspire, the Inspire Board, Merck and Offeror in the United States District Court for the Eastern District of North Carolina, under the caption Norris Foster, Noah Alpern and Louis Alpern, individually and on behalf of all others similarly situated v. George Abercrombie, et al., No. 5:11-CV-00180, to include certain federal claims.  In addition to claims alleged in the original complaint filed on April 14, 2011, the plaintiffs in the amended complaint allege the Inspire Board, Inspire, and Merck disseminated false and misleading statements relating to, among other things, the sales process for Inspire in violation of §14(e) of the Exchange Act.  In addition, the amended complaint also alleges certain control person liability under § 20(a) of the Exchange Act against the Inspire Board, Inspire, and Merck.  On April 22, 2011, all defendants filed motions seeking to dismiss the case.  The court has not ruled on this motion.  That same day, plaintiffs in the North Carolina action also filed an emergency motion for expedited discovery and to set a briefing schedule and hearing date for a preliminary injunction hearing.  On April 22, 2011, defendants filed an opposition to that motion.”

Item 12.

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:
 
     
Exhibit (a)(5)(B)
  
Joint press release issued by Merck and Inspire, dated April 28, 2011.
 
 
 
 
 
 
SIGNATURES

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

             
       Dated: April 28, 2011
  
MONARCH TRANSACTION CORP.
   
 
By:
  
 
/s/ Katie Fedosz
       
Name:
  
Katie Fedosz
       
Title:
  
Assistant Secretary
 
       Dated: April 28, 2011
  
 
MERCK & CO., INC.
   
 
By:
  
 
/s/ Katie Fedosz
       
Name:
  
Katie Fedosz
       
Title:
  
Senior Assistant Secretary

 
 EX-99.(A)(5)(B) 2 dsamendex99_1.htm dsamendex99_1.htm
 
 
Exhibit (a)(5)(B)
 
 
   
 
 
Merck      
Media Contact:
 
Ian McConnell
(908) 423-3046
Investor Contact:
Carol Ferguson or
Joe Romanelli/
(908) 423-5088
 
 
      
Inspire Pharmaceuticals, Inc.
      
 
Cara Amoroso
(919) 287-1266
  
Jenny Kobin
(919) 287-1219

 
Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period
Relating to Tender Offer for Shares of Inspire
 
WHITEHOUSE STATION, N.J. and RALEIGH, N.C., April 28, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR") has expired in connection with the previously announced cash tender offer made by Monarch Transaction Corp., a wholly owned subsidiary of Merck, to purchase all of the outstanding shares of common stock of Inspire.
 
    As previously announced on April 15, 2011, Merck commenced, through Monarch Transaction Corp., its tender offer for all outstanding shares of Inspire for $5.00 per share in cash without interest and less any applicable withholding taxes. The tender offer is being made pursuant to an offer to purchase and related letter of transmittal, each dated April 15, 2011, and an Agreement and Plan of Merger, dated as of April 5, 2011, by and among Merck, Monarch Transaction Corp. and Inspire.
 
    The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer. The tender offer and withdrawal rights are scheduled to expire at 12:00 midnight, New York City Time, on May 12, 2011, unless extended in accordance with the definitive agreement and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Consummation of the tender offer remains subject to other customary conditions described in the tender offer statement on Schedule TO filed with the SEC on April 15, 2011 (as amended), including the tender of a majority of the outstanding shares of Inspire's common stock, determined on a fully diluted basis.
 
    The Depositary for the tender offer is Computershare, Inc., c/o Voluntary Corporate Actions, P.O. Box 43011, Providence, RI 02940-3011. The Information Agent for the tender offer is Georgeson Inc., 199 Water Street, 26th Floor, New York, NY 10038. The tender offer materials may be obtained at no charge by directing a request by mail to Georgeson Inc. or by calling toll-free at (800) 279-6913, and may also be obtained at no charge at the website maintained by the SEC at www.sec.gov.
 
About Inspire
 
    Inspire is a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Inspire's specialty eye care sales force generates revenue from the promotion of AZASITE® (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis. Inspire receives royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% and DIQUAS™ Ophthalmic Solution 3% (diquafosol tetrasodium) in Japan. For more information, visit www.inspirepharm.com.
 
About Merck
 
    Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
 
Notice to Investors
 
This release is neither an offer to purchase nor a solicitation of an offer to sell securities. The offer to buy the outstanding shares of common stock of Inspire is being made pursuant to a tender offer statement on Schedule TO containing an offer to purchase, form of letter of transmittal and related materials filed by Monarch Transaction Corp. with the SEC on April 15, 2011. Inspire has filed a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer with the SEC. The tender offer statement (including the offer to purchase, related letter of transmittal and other tender offer documents) and the solicitation/recommendation statement, as they may be amended from time to time, contain important information that should be read carefully before making any decision to tender securities in the tender offer. These materials have been or will be sent free of charge to all stockholders of Inspire. Investors may also obtain a free copy of these materials (and all other tender offer documents filed with the SEC) on the SEC's website: www.sec.gov. The Schedule TO (including the offer to purchase and related materials) and the Schedule 14D¬9 (including the solicitation/recommendation statement), may also be obtained for free by contacting Georgeson Inc., the information agent for the tender offer, toll-free at (800) 279-6913.
 
Merck Forward-Looking Statement
 
    This news release includes "forward-looking statements". Forward-looking statements are statements that are not historical facts. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
 
    The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the United States and internationally and the exposure to litigation and/or regulatory actions.
 
    Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2010 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
 
Inspire Forward-Looking Statement
 
    The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including: statements regarding the expected completion of the tender offer or merger, including the timing thereof, and satisfaction of the conditions necessary for the consummation of the tender offer; Inspire’s ability to develop and commercialize its ophthalmology business; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Inspire stockholders will tender their stock in the tender offer; the risk that competing offers will be made; the possibility that various closing conditions for the tender offer or merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the tender offer or merger; the effects of disruption from the tender offer or merger, making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; other business effects, including the effects of industry, economic or political conditions outside of Inspire's control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in documents filed with the SEC by Inspire. Inspire does not undertake any obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law.
 
# # #
 
 GRAPHIC 3 merck.jpg begin 644 merck.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_[0P@4&AO=&]S:&]P(#,N,``X0DE-`^T* M4F5S;VQU=&EO;@`````0`$@````!``$`2`````$``3A"24T$#1A&6"!';&]B M86P@3&EG:'1I;F<@06YG;&4`````!````'@X0DE-!!D21E@@1VQO8F%L($%L M=&ET=61E``````0````>.$))30/S"U!R:6YT($9L86=S````"0`````````` M`0`X0DE-!`H.0V]P>7)I9VAT($9L86<``````0``.$))32<0%$IA<&%N97-E M(%!R:6YT($9L86=S``````H``0`````````".$))30/U%T-O;&]R($AA;&9T M;VYE(%-E='1I;F=S````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H` M!@```````0`R`````0!:````!@```````0`U`````0`M````!@```````3A" M24T#^!=#;VQO65R(%-T871E`````@`!.$))300"#$QA>65R M($=R;W5P)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7 M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*! MD12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7 MI[?'_]H`#`,!``(1`Q$`/P#U5))>??7#Z\YM/4+.F=(M;0W&.S(R(#GFS\^J MOU):QE7YS]O\[_X(1$DT&/+ECCCQ2_!]`3KRCI'U_P"M8&0PYMYSL.?TM=@; MZ@:?I/JM:&NWL_L]*K-N)C6=0H`9F"RMC[7.'_:FQSV^I9]I M_G/6=_A?47'_`%SZ#E=+ZMD9)8YV#EV.NJO`):'6$V64V.'T'ML<_9^_6NL^ MH_U5PL;IU'5^SZ?^#3Y"/`"-_P"6[0QG M++F)B0X@.DOE`Z<+L=0POJQT[$LS,W"Q*J*Q+B::]?Y#&[?>]_YC%YQT[ZY] M8Z?G'(98YV$ZPN=T]QW5MJ)_H^-/]']&OVT>E^B_X/TUZ3UWZN].ZYBFK*8! M^MT1N;QN;^_7^>O)L3HO4LWJ3^E8]6_*KL=3<1.RLL)KLLM?^96W: MEC$:/$GFOQME9XEKQO9_T2O&LWZQ= M=Z=]:<[.;F9=N'T_J+O6H-SW5>D;7M^SNJ2&-#`7?YJ\R^KW3*.M?6'ZY]+L<-N5ZK`9G:\7VNIM]O^ANV6)C= M%T+WZIO\8WUFR[\_$Z?T7+MKKIQCFY%F-8ZLN:]OJ5[WL=6[TZ<9OVC_`*_4 ML')ZWUIGU)QLD=0RS?\`M*]AL]>W>6-I:]M1LW^IZ>[\Q7>C]`OP_J1]8^K9 MS#7E65/PJVNF6LH>*\F'3]%^4STMO_=58N78W_F'BECVS^UG55E;K;/6:ZO=ZNS^1_+6YT;-_Q7V9[6=!I M:SJAJO\`0>&7-B*;77>ZW]&W]`+?I+"^JOU:_P"<7U!SJ\:/MV+F&W%(,!Q% M&)ZF-9_)MV^S_1W^G8DIO8W^,?J]'U)KLW<[TZV57/R+*VC M9=DT_::L5K/\)=LLM]3]*KU'^+SZUY>.,W.^L63C]3>W>*VOL MK9^D]3U_^"798G^-OZJOZ<,C,L?1EM;^EQ&L+W;P-?1L;^B>QSOYOU+*_P#A M?324Y3.J]0Z;_C"QJ.J=0M;BXF`U^UEWI_P`]F.=].[T\7^9K>L_= MA]9_QGX_VBL.QNHX+768[R#[+<1UGI/VG\W^0C?5S.O^H_UGM^K'5+9Z7G.# M\'(>=`YVE-L^W^?V_9LOV^S*K];^:M24_P#_T?5"`001(.A!7E_UTZ#U+IO4 MKLS']9W3LDFUKJW/+:G'6VJQK#^A9O\`=5_@]B]121B:-L6;",L:OA/20?%N MC]-ZQUK)9CX3KRUYBS(W6>G6/SGOLG9[?]'^>O8L3%IQ,>O'I'LK:ULG5SMH M#-]COSW^WW/1DZ4I<1VI&#`,0.ID3U*D*O&QJK'VU5,999]-[6@.=W][A])% M209F#JJWL=6]H-4QXF'-8T$2-IU`_=1*<>C'9LHK94PF2UC0T3XPU$224A9B8M=KKZZ M:V7.G=8UH#CN.YVYX&[W.4'=.Z>]SG/Q:7.<27$UM))/)=[59224B&+BBX7B ME@N`@6;1N`C;&^-WT4KL7%R-OVBEEVV=N]H=$_2V[AY(J22G_]+U5)?*J22G MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]D` M.$))300A&E9E2!I;F9O`````%4````!`0`` M``\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(` M90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@Q*4$5' M(%%U86QI='D`````!P`(`````0$`_^X`#D%D;V)E`&1``````?_;`(0``0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@(" M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`10"8 M`P$1``(1`0,1`?_=``0`$__$`:(````&`@,!``````````````<(!@4$"0,* M`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,# M`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F M-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I M.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6V MM[BYNL3%QL?(R'EZ>WQ]?G]TA8:'B(F*BX MR-CH^#E)66EYB9FIN]^Z]U[W[KW7O?N/7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_T-_CW[KW M6&HJ:>D@GJJJ>&FI::&2HJ:FHE2&"G@A1I)IYYI&6.*&*-"S,Q"J`238>],R MJI9B`HXD\!UIF5%9W8!`*DG``'$D_+JC7O[_`(4&?`;IG/UNV-I9+?W?V4QN M1DQV1R'4N"QLVT8G@!\\U%N[=>9VWB]P4:R+H2HQGWM-,;-'(T9U^SVSY7W^ M^5BED(E`)#3-X8)#4II`>4'B06B"D"NJC*3C]S#]Y3VYV.^N+"T^KW&2,T,E MLD9A+!BK`2221ZP*5#QJT;@KH=@:@R'P\_F[_"SYI[AQNPNN][Y;9G:N4I&J ML?UAVAB4VON/+2002U5;0[=R%/693:VYLC14\$DTE+0Y":K\"/*(C&DC(DW# M9MSVQI#>V3+`"0)!1D8:@H-5)*ZBRZ!($9M0HI8,`)^1O>OD7GZ]_=FV7A2PM`]EW4M]>]^Z]U[W[KW7K_`/%/ M?NO=>]^Z]U[W[KW7K^_=>Z][]U[KWOW7NO7]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=?__1W\JBIIZ2">JJYX::EIH9:BIJ:B5(8*>"%&DFGGFD98XH8HU+ M,S$!5!)-O>F94!9F`4"I)\@.)ZJS*BEF8!0*DG@!QK^SK7U_G(?)#L#N_H7) M?%[X$U(^0F\MXYIL/\BX.B*FF[+S'776T5(DT.W-SG:=5D!M>?L;,2I3**BS MU-%0UU.%LSE3+99ML@W*PN=V$RV6EI8G59&1Y(G32*HC$A&.HZ2-+(H1=&*!0-,,O@+(8Q<.U0VM"R0O&0Z2,!J M7#^6U\^S:WQ!^0)O:UNM]Q\ZM%K?Y%S?R+;_`(,/ZCW)O]<^6_\`E/?_`)P7 M'_6GK#O_`%L_<7_IA-W_`.R.?_H#IRPW\O'^8E@,QBL_MWXI_)'"9_"Y+'Y; M!YC"[#W9CLOB> M*6&:Y9X'4@J;:<@J000082""#0BE"./'I^'VZ]R[::&YM^2MZCN(V#(RVMPK M*RG4&5@@8$$5!!J#0BAZWS_@_P#,?;_=W4/5^VNX-U[4V/\`+:DV=@Z7N7HG M<61IMH]I[9WBB-2/-ENM,_7)N_"C<]/#%E*6&>$R&FK8S^0/<2W"I;R2CQ*V MQN)8XG;`E$<^0;YL6QV7,M_;VW/ACT7%G(Z1 M77BIJ&LVS".1#*BB?0(PJJ_;50#U8!F[\O1X#:^V,%VKM.OS.?S>1F6GQ^)Q=##D6GK,A M6U$BQPQ("\CL%4$D#W[KW1TLOE\5M_$Y3/9W)4&&PF$Q];E\SF,K5T^/QF)Q M6-II*S(9+)5]7)%2T-!0T<+RS32NL<4:EF(4$^_=>Z(;1_S6_P"6I7U=+047 MSH^,%365U3#1TD$?<&SM<]54RK#!"E\F!JDE<*+GZ^_=>Z$#MG^8)\(.A]]9 M3K+N?Y6]$]8=A8.''U&8V9O7L;;>`W'C(.OQU7%/$6 M7UQR!AP1[]U[I([:_FA?RZMY;BP&T-J?-3XW;BW3NK-XK;>V\!A^UMJUV6SF M?SE?3XS#X?%T,&0>HKQ52])DL1EL?4Y!*BBKZ&JC:.6-P& M1U((N/?NO="%TO\`-KX>_(S.3;7Z)^3W1';6Z8(I:A]J[$[0V?N'=/VL$#5$ M]8FVZ#+2YN:@A@5F>=(&A4*UV&DV]U[HT#NL:L[LJ(BEF=R%554%F9F)`"J! M_=>ZKI[&_FY?RT>I]R5.T=[_-+HNCW#1$"OH,'NK^^8H9#'')]O6UNR MJ7<./I*M4E75#)*LJ\@BX-O=>Z&?_9[OA<>HIN_(_E1T)4=*TVX*7:59V?2= MH;1K=F4&ZJY&DI-M9+.4F4FH\?GZB%-:T<[1U)2S:+$'W[KW0S=2=Q]4]];& MQ?9O2O8>T.TNO,U/DJ7$[RV-G*'<.WNR&U-G15[XHXV=_M*C(Q5,\D M%,%++]3.A!D$@*J?#AD&A4[D:2/Q@7K%H*E_)$^5Y(X:?!X_(35%'7 MSN1'1T>0DJ7.F!@3'G79Y]PMK:]M$+W%MJJ@R2CA=>E:$M(I1"`#\(=0'JI*JGE62.2-F1T8, MI((/N*@RL%92"I&#Z_9UTHM[BWN[>"[M)TEM945T=&#(Z,`596!(96!!5@2" M""#3H*^\^]NJOC;UCN?N#N?>&*V1L+:E&]3D&&6YGAMH(R\\C!5`&37/EY`5+$T55#,Q"J2"O MF#F+8^5MMEW?F'JVYBEJ8X-IX>+(1"&26HVY@*&CI?.@C M\CT^L!+V]S=M&TQ;=L]OM,X$BZ'U@]RLTC,\@X*"FIR!J7*TU9J3RCYKY@FY MHYEWSF*8,DEY=22A6V;D5IZ.IK*A6 MJ*N"KI9)IIZ@S/[C/FO9TVGT-Q[*['Z\QFY\ M9)B*_*U'6>[Z.CFFI):B3;F^*;`[MVGDY8Z:HG:ECSNV,Q25\"2A)32U43Z` MKK?W7NK]/YS^P=I=K?\`"@9.K=_U570[%[)[.^'6P=Z5U!EW=R55'F\K#48O#U=-ALC,\=741R04[@22*R*P/NO=;$O4/_``G:_E:=5]L] M7]G[)[<[KR.\^M^Q-E;]VCCZ_NWK3)T%=NC9^YL9N'`4-;CJ'KNDK:^DJZ<7E:'&8JOC MP>Y,B)9:%ZI)6:MQ]=&LC1((H_=>Z./_`#K?YK'R.^12_&3X(=&Y'/;;W'V5 MT]\>=V?(7;^R?/@]Q;\[K[UV?M+=FV.GZ6OCJZ6MAVQ00;IH9Y:"U.M76Y". M.HUI2H/?NO='Z^,G_"3[XUXSJW"3_++N'MS=GP2A^\6(2+1TNHI[]U[HI/\S'^6#3?ROOY M4'R8ZZVWV3/V7UQVA\Q/C]OG860S=%'0;VP]%0[2W%@\KAMW1T%+38&MJX*^ M`24]91"):B&3UP0N@UVJ"H%,U/7ND3T1_,]'\N_^0'U!M'K/,45/\H_D3O;Y M!X?J[[*IH6RO7NU5[$W'AMR]RU]&F.@E2KP.4224]'-215 MZ]T>+_A-K_*OR>P,$?YCGR0P=9-V[V;39C_0%B]V035.X-K[,S_W5)N7MC*) MFJ9LA1[O[,BGJ:>@J=0G.WJB:7R/'E2$]U[K_],O'\X3X\;P^/7\P#Y!Q;EI MYI,/W#O_`'7WQLG,^"H2CR^W>U=RYC=%1#23S4M+%42[=S];5XV<1F14EI>6 M;ZF7N4-T7<-J2!@HN[8B-@,'30F-P*DT9``6(`,B2!<*.N6_O+L&X\O>Y'-D M6X(0MU>2W434;2\5P[2J5+*NK3J,;Z05$L;H&;23T`GP6^'F]OG-\CMH="[+ MJ1B8B3D#DK<.?^:-OYU\9/1M6[Q['WEG8LK6U[1RY+*-M:3,Q[&P\]54QZHX\?C*2*F4E8@NIRT) M3%KB\N;Z4*+B9RSZ`54LW$A`2H.!W&KG)9V8LS=*>1_;[9>0MNMMOVF[OI5C M1EK-4RV'Q6*R#PJJUF*BH*R"5_)*]1&&A M9=M&Y3;#=S7]G;I+,ZT8/FJA@VE&)K'7(%#X=2&>-]*T!?NM[,[=[B6LM[!N M5U#S#"CF'5-));,Y"=C12%UB5M%-5OX5&8R.LQ&@_/:W9M;/[&W3N79.[<74 M83=.S\_F=K;EPU486JL1N#;^1J<3F<74-!)-`:C'Y&CEBOY`_)BNBFH-CKMO&].;?,U#5*FY-QU> M6QV[=PU%#D&$=(]/M:@QE%'/&OD+2Y-+E/&0\6\]744^YV%K$U7MXGUTR`93 M&47U#!8RS`T(5XSD/C+3[J&P73[MS1S0P9;&.V6U6J,%=Y'65]+_``DQ")-: MY:DR$Z135M.?(:XZ#[NTWN>H^QA<M M`[_A.Y\8-C_,O;W\RKXV]@4E-+ANT/C;LS#X_(S013S;7W9!N_+U^S-XX[S1 MRI'D]J;II*6OA.DAF@T,&5G4^'P-]H_R]>Z(-\`/A+W-\IOY@/4WP*[4BWD= MH]+=H[VRG;NQ,KF:_P#@76FU]HY?'-W'48O"Y.;[##3[TK]NX_%SRTD$_P`=,/A\1C*.GQ^+Q&(Q M?1O2U#C,5C,?21PTE#C<=0P1PT\$2+'#$BHH"J![UU[HSO\`.5ZVV[W-_P`* M#Z7I_=TF2AVIVMVI\-.MMT28:IAH\O%MW?6W^J=K9J3%5D]-6T])DTQF4E,$ MCPS)'*`2C`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`1SW[? MUQ[9S#;O^F^J*:,JLT1J-01V5QID`"R(RLK"C%=:(Z:_>]NHZ;_`(3K M#)=_=3;=R'RKVW\@:BFZNR%1ON?&;"S'4:X!EW-BJ9MR;?QFX9=P4>^Y6J1. MB8_&TZ38NE+LS^))#_Q]PYQW*VM;R[MK?PXY3$PC))8F(E"K3!F.A&;L*@!2 MS*133CC?;)+]V26YYFVJV7>=IW-S;5F"036A5O%@3QE\1I5EC$HF"0Q(SPQ. MVBB1D+?^@HO?O_>'>T/_`$_X>S7_`%O[[_H^Q?\`9,W_`&T]%?\` MP6VX?],/#_V5/_UHZ]_T%%[]_P"\.]H?^CES'_VO?>_];^^_Z/L7_9,W_;3U MO_@MMP_Z8>'_`+*G_P"M'1DNK_Y075/\R'<&$_F*]^YG?G6U+\G\7B^T\C\< M-K>%*?$BOH\=CL56_P"DW)/)F;'[(;)[I./I;O; M;;=PUP;&(=Z.[4,HN9@Y>.X(:Y11;H`LRK&Q106V/.LNL=@=,[!VMU?U;M/$ M;)Z_V7BH<+MG:^$IS!C\900%V(!E>6IJZNJGD>>IJ9Y):FKJ)))II))9'=B$ MU)+,2S$DDDU))))+$U)).2222TO[^[`WOL;[_P#A7]\MI;BVM_%/M!7_`,-_C^(J M\4*_[(ST@K/M/NQ)X_-$7TV#H?4+`T((Z,NJ5?Y1'\E'_AJS?W<>^!\EO]._ M^EK:&W-J?PS_`$-?Z+_[O_W>S5;E_O\`[W_2MV'_`!;[O[OQ^+PTWCTZM;7L M-`G21\_\_7NC[=-?`7IGI'YD_)[YJ;3@*]B?)_;O7^$W%CCCX*>AVU/M05QW M9D\+402C7+V750XBJRB&&.]9B5GU/+43LWNO=4Z_.#_A.)0_,[YO[]^8\GS! MJ^N8=_[DZ^W!DNMDZ%AW9)1C8VUMI;3DHZ'>;=Q[;4#+46TTD#OB7^WEF:ZR MJ`OOW7NLW\QC_A.E4?/KY?[]^6-+\S9NFJK>=%L:FIMFT_Q_?>\^"GV3M'![ M7BK(=VQ]Y;)DJ9JQ\,*E;8^`T[.$!?1K;W7N@1Z*_P"$O^\^F>[^G.X*K^9% MNK=]-U1VKU[V54[4D^/N5PZ;G@V+N[#[HFVZ^6D^2>:CQ:9J/%FF-2U'5K`) M=9AETZ#[KW1Q^FOY#R]3_P`TW,_S,*CY4R[GFR7;W=':]+TQ_H.H\+%0/V_A MM[8,;<;?Z=HY)*FCVK0;U=8*@8**:?[6)FTN68^Z]T;;^:Y_*DZO_FE=4;1V MCN#=W^B3M+KC/OE>N^XZ3:";VK,%BXNBL3DT#2;:PF?RG8G;<&XL!22`4\%!6(,8N+BIJ-Z5UH,?)2>Z]U5S0 M?\)-]V;9.DBVI/O'?46*@H(<@ ML!6*N:.>1'G*(\KCWKKW528_X3I_Z+_GA_L[GQ`^9-9\:?LNRO\`23M_J3_0 M+_?W!X7^,2>??.P_X[1]U=?_`'G7.[OO*ZD_AAQT?V>*K/M5D?Q)+[]U[K__ MU=_CW[KW0!?)GXX]9?+'I7>_1/;>&CRVT-YX\1>=04R6W\W1N*K!;HP54K)+ M19O`Y*-)X75@L@5H90\$LL;VCEN()$N+68Q7:&J..*M2E:>8H2&4]K*2K"A( M(9YOY2V7G?8KSE[?;826DHJK`4>*0`Z)8F_"Z$X/`@LCAD=U.D3W[_PGV^?W M5&?K8>M=L;7^0NT?XE)!A]Q;&W+A-MYJ;'$:Z:MSNT-[Y;"U&(JY``LL-)5Y M2**2X69T'D]R?9\][9*&&X6TMN5!-0/%0]W:%T`R%B#4UA"BA%30$X%\P_=P M]RMIO9X=JL(]RVX&J2Q211EE+$+KBED1U?30LJ>(JZJ"1P&/1KO@G_PG=[PS M78NT=^_---K;&ZLPE12YK+=2XW/Q[FWUO66(220;9R]?MFI;;NU\.TX1JVHA MR%;4R1*8(X4,GW$)7O7.:W5O=6.U131LS4\8D+VAA4QJI9N]-2AF,3QU5E!; MX1=[>?=HYANMV@O>?X8[79H7#&W619);BFDZ"T+LD439#N)/%[2JJNH2KN;8 M_'4.)H*#%8NBIL=C,924V/QV/HJ>.EHJ&AHX$IJ2CHZ:%4AIJ6FIXUCCC50J M(`!8#W'X4*`H&!2E.&,?8,=9S6]M;VEO!:VL"16L2!410%5%4:5554`*JB@4 M```"@`'4_P!WZ>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=?_7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z ,]U[W[KW7O?NO=?_9 ` end GRAPHIC 4 inspirenewsrelease.jpg begin 644 inspirenewsrelease.jpg M_]C_X1*K17AI9@``24DJ``@````,```!`P`!````OP````$!`P`!````5@`` M``(!`P`#````G@````8!`P`!`````@```!(!`P`!`````0```!4!`P`!```` M`P```!H!!0`!````I````!L!!0`!````K````"@!`P`!`````@```#$!`@`> M````M````#(!`@`4````T@```&F'!``!````Z````"`!```(``@`"`!0GAL` M$"<``%">&P`0)P``061O8F4@4&AO=&]S:&]P($-3-2!-86-I;G1O)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V M-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3 M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1`Q$`/P#U5))9?7NNCH>*,NS"R[&Z7TWJ&7:QI>]K*Z@&M'YSG.R&H=W^-C MH.+F_8L[#S\*]KPRT7U,;ZW])[/S$E/;)*O?E"O#=ET,=E@,]2 MME&USK`1+?1+W,K=O_-_2+G^F?7W!ZCD9%0P,W%JP=WV_)R65UU8Y8'.#TRCJ_H9.1TS(!(RZ:PYC8?Z+?6W/8YGJO_FTE/1I+E,?_`!A= M/RNFV=6Q>GYU_3J7EEV2RNLAFT-=8]U7K^OZ537_`*1[:U/+_P`8OU;Q<2G/ MW77X%_M;ETUE]8LY.+=P^G)V?I/2M9_-I*>H27,XGU^Z3G85O4,+%SG9[MJR?_'-^KOVX=.->6W/ M-@I&*Z@BSU"=K:ML_2W)*>M27-7?7WH^-G48&=1F8-^38VJHY%!8PN<0T?I9 M+-ON]RZ24E+ID'*S<7$J-N3:VEGBXQKY?O+.J^M70[;!6,C9,PY[7,:8T^F\ M!J=''.0N,21X!CGFQ0(C.<8D]"773J+7-(!!D'4$<$)Y361__]#U54>NZ=$Z M@?#%N_\`/;U>5#KW_(?4?_"M_P#Y[>DI\T_Q(_TSJW_%4?EL6G]=?J<_ZR9_ M5J_5_P"M>?A_4]G7 MS^GCIG^*C+PJ[V95%32<;(K=O:^ ME^3ZV,[ILG\SUMW_7-Z2G=_Q:Y6+A?XO^H9.8YK<: MN_(<_<1!;Z=0V:_2W_0V+@>EXV8SZD=;RK&EN'==B,I)&CK6/>YYJ/\`P53M MMG_&+N/\4O1>C=1^K^3=GX=&5=5G/VFY@>0!70YO\Y/[SEJ_XV*ZJ?J4ZJIK M:ZVWTAC&@``2=&,;[4E+?XKC_P!@I\KG=;ZEU'`ZC4VVFS!=!(]S'>I6UMM3OS+&)*=CZ MM,OZA_C6S.I](EW36V7')R&`FIS"S9'J?0?ZV3^DK_[=6?UVQK?\;XL>YK&, MSL3XN=\%9^I'7>H_5/ZSO\`JKU6W]1=JJO6ZVV_P"-WT[6BQC\_%:YCAN!:64^US7?R4E/H/4<[HWUKZED?55I MKR\=N([(NRZG!YIO#ZZL;T'M]GK5^H^W_P`#_P!(NDQ*[Z\6FO)L%M[&-;;: M!`>X"'V;?S=_TESU'UW-`(8QEK7U6-M97]%C'TM? MZFW\]:/U:ZM;UKI#.IV,%=>59:[&;$.%#;'UX[K-7?I'U,]1R2GC^J9M_5<^ M_*RM[C12ZO'H.EMEECO5??;5_@ M:6N=N97:K5-8PHNO-SL MVPGWOM;8ZLU.?_HZV[7_`/">KZBVH$$QQQ'#$5PYO[KVN>YKD;"^IG1\'J1ZIC/RFYEC@Z^TY-KO5C\W):][FW, M_DN6Z2`)/`3->U[0YI#FD2"#((/<)*7A85OU*^KUN(_"?CDX=F8>H/Q]Q##< MYOI.;M;&VC\_T/YM;C'M>P/80YKA((,@_`A224\ZSZE8%>$[IE69FU]+?H[` M%WZ/9^?0RUS3ELHL_P`)4S(1>H_4WH?4L.C`OKMKP,9H97ATVOJI@'<'/JJ< MUMEG\NQ;J22G"Z']3.B=`O-W2A?0'3ZE/K6.J>8V[K*7N=6][/S'(O7?JOTO MZP!E?5/6LHKU%#;7LKW#BQU=9;NL]RV$,Y%#7%KK&M<.07`%)3B87U+Z/T_! MNZ=A/RW]Q`Z9_B]^K?2,MN;TQE^+>W0N9?9[FG5 MU=C7.+FG?7E,YG\ MO?7_`()>EY%&'GX]F+D,9D462RZIP#FF/S'M5/!^K'U?Z=D#*P,"G%O:"T65 M-VF#R/;]))3G=4^HV#U=@JZEU#J&30/\`Z\"N1PYU;*VM>[^NMKIW3\;IF!C MX&*"W'Q:Q76"9,-_>/[RMI)*:6=TO"SC6_(KFVDS7:W1S?+=^X[]Q41]5>F' M:+S9>QI:0QY`$M'I@NV-;N_1[:W?\76MI)/CDG$4)$4Q3P8IGBE`$L:ZV5,; M76T,8T0UK1``'9H"DG23&5__TO54DDDE-'K8_P`C9\ZC[-=_Y[>N7_Q;Y%^% M@8_0I=/>1&['R6M??3I^=AYS[&>]W\S=2NIZW_R-G_\`A:[_`,]O M7,'&NK^IWU?Z]AL+\[HF'CY+6")LQS16SJ.+[O\`38OOK]O\_34DI%]7NMY' M3_JG]7NG=.QVY?5.HTN&-4]Q94UMO^N>5@=. MZC9U+!#.H=&?1]MHKL)K?3>YM;,["N=7^DK_`)QWI/;^C]+TK7KEL/#HKZ;] M5NIYV3DX/3GX+\.[-Q+74>C8^QMN,F=7 M'UAQNG7YF=3=C#I[.JYEYR:K'EM[G,PW6`.HVSTW_`.#_`-)QM.'8RTOMJLL:;,:C.I=6WWY<;6.I_F;/T=ZP\[I^;7T7K?U$EUEM5'VS MH;G`.-N(U]=WV-NR7.R,:ZIV-^D]]GJ5V>GZ*A4?JWG7](;B=1ZKU;)RLBJQ MW3;,QUAQA4X6VW]1HL]1E/V.P-]EG\]_VGWI*;/0.MGI&/UWT:#EYN9]9,O& MP\5IV[['>D[WV0[TJ:F,?9=;M]BW^F=?ZC]NR.D];Q&4=1Q\<9E?V1SKJ\BF M=ECL?H])KQND9MU=.P6N.70V]S:L>_*I] M/TONZ9TS*_:^3UOJEF1BWV7676/KQ!ZU7VO( MNQ6[WU/TM?I?OK1ZCU#I.)D=6ZCTG.OZ)]8,?)L8_I$^K7F7 M;]F/9^S'MW7NZG7Z7ZQB_P`QZWK?\+8E/4=1Z[U:SJMO2>@8E.7D83&6Y]N1 M::JZ_5EV/BL]-MEK\F^MKK=^ST*6;/\`2+0Z'U9O5^FUYHK./82ZN_'<9=5= M6YU.10\C_1VL=[OSV>]<;E4X=/UBS[?K%U#+Z"_J%6/E8[L?+?10_P!.BK&S MB]FR^MMK)G:]H<)\8^UJ^64DE/U,S'QZ]^RIC?5.ZS:T#<3^<^/I)G8V. MZYM[JF.N8(;:6@N`U^B_Z7YR^6DDE/U-=CX][`R^MEK`=P:]H<)_>ARG`^]? M*R22GZJ27RJDDI__V?_M&890:&]T;W-H;W`@,RXP`#A"24T$!```````#QP! M6@`#&R5''`(```(````X0DE-!"4``````!#-S_I]J,>^"05P=JZO!<-..$)) M300Z``````"C````$`````$```````MP'1E96Y":71B;V]L``````MP.$))30/S```````)```` M```````!`#A"24TG$```````"@`!``````````(X0DE-`_4``````$@`+V9F M``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@````8` M``````$`-0````$`+0````8```````$X0DE-`_@``````'```/__________ M__________________\#Z`````#_____________________________`^@` M````_____________________________P/H`````/__________________ M__________\#Z```.$))300(```````0`````0```D````)``````#A"24T$ M'@``````!``````X0DE-!!H``````UD````&``````````````!6````OP`` M`!(`:0!N`',`<`!I`'(`90!N`&4`=P!S`'(`90!L`&4`80!S`&4````!```` M``````````````````````$``````````````+\```!6```````````````` M``````$`````````````````````````$`````$```````!N=6QL`````@`` M``9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG```` M``````!,969T;&]N9P``````````0G1O;6QO;F<```!6`````%)G:'1L;VYG M````OP````9S;&EC97-6;$QS`````4]B:F,````!```````%7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P`` M``$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<` M`````````$)T;VUL;VYG````5@````!29VAT;&]N9P```+\````#=7)L5$58 M5`````$```````!N=6QL5$585`````$```````!-'1415A4`````0``````"6AOD%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI M8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````1 M15-L:6-E0D=#;VQO)E\K.$P]-UX_-& M)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(! M`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R M@I)#4Q5C+RLX3#TW7C\T:4I(6T ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1`Q$` M/P#U5))9?7NNCH>*,NS"R[&Z7TWJ&7:QI>]K*Z@&M'YSG.R&H=W^-CH.+F_8L[#S\*]KPRT7U,;ZW])[/S$E/;)*O?E"O#=ET,=E@,]2ME&USK`1+?1+W,K=O_-_2+G^ MF?7W!ZCD9%0P,W%JP=WV_)R65UU8Y8'.#TRCJ_H9.1TS(! M(RZ:PYC8?Z+?6W/8YGJO_FTE/1I+E,?_`!A=/RNFV=6Q>GYU_3J7EEV2RNLA MFT-=8]U7K^OZ537_`*1[:U/+_P`8OU;Q<2G/W77X%_M;ETUE]8LY.+=P^G)V M?I/2M9_-I*>H27,XGU^Z3G85O4,+%SG9[MJR?_'-^KOVX=.->6W/-@I&*Z@BSU"=K:ML_2W)*>M2 M7-7?7WH^-G48&=1F8-^38VJHY%!8PN<0T?I9+-ON]RZ24E+ID'*S<7$J-N3: MVEGBXQKY?O+.J^M70[;!6,C9,PY[7,:8T^F\!J=''.0N,21X!CGFQ0(C.<8D M]"773J+7-(!!D'4$<$)Y361__]#U54>NZ=$Z@?#%N_\`/;U>5#KW_(?4?_"M M_P#Y[>DI\T_Q(_TSJW_%4?EL6G]=?J<_ZR9_5J_5_P"M>?A_4]G7S^GCIG^*C+PJ[V95%32<;(K=O:^E^3ZV,[ILG\SUMW_7-Z2G=_Q:Y6+A?XO^H9.8YK<:N_(<_<1!;Z=0V:_2W_0V+@>E MXV8SZD=;RK&EN'==B,I)&CK6/>YYJ/\`P53MMG_&+N/\4O1>C=1^K^3=GX=& M5=5G/VFY@>0!70YO\Y/[SEJ_XV*ZJ?J4ZJIK:ZVWTAC&@``2=&,;[4E+?XKC M_P!@I\KG= M;ZEU'`ZC4VVFS!=!(]S'>I6UMM3OS+&)*=CZM,OZA_C6S.I](EW36V7')R&` MFIS"S9'J?0?ZV3^DK_[=6?UVQK?\;XL>YK&,SL3XN=\%9^I'7>H M_5/ZSO\`JKU6W]1=JJO6ZVV_P"-WT[6BQC\ M_%:YCAN!:64^US7?R4E/H/4<[HWUKZED?55IKR\=N([(NRZG!YIO#ZZL;T'M M]GK5^H^W_P`#_P!(NDQ*[Z\6FO)L%M[&-;;:!`>X"'V;?S=_TESU'UW-`(8QEK7U6-M97]%C'TM?ZFW\]:/U:ZM;UKI#.IV,%=>5 M9:[&;$.%#;'UX[K-7?I'U,]1R2GC^J9M_5<^_*RM[C12ZO'H.EMEECO5??;5_@:6N=N97:K5-8PHNO-SLVPGWOM;8ZLU.?_HZV[7_`/"> MKZBVH$$QQQ'#$5PYO[KVN>YKD;" M^IG1\'J1ZIC/RFYEC@Z^TY-KO5C\W):][FW,_DN6Z2`)/`3->U[0YI#FD2"# M((/<)*7A85OU*^KUN(_"?CDX=F8>H/Q]Q##P/8 M0YKA((,@_`A224\ZSZE8%>$[IE69FU]+?H[`%WZ/9^?0RUS3ELHL_P`)4S(1 M>H_4WH?4L.C`OKMKP,9H97ATVOJI@'<'/JJ8V[K*7N=6][/S'(O7?JOTOZP!E?5/6LHKU%#;7LKW#BQU= M9;NL]RV$,Y%#7%KK&M<.07`%)3B87U+Z/T_!NZ=A/RW]Q`Z9_B]^K?2,MN;TQE^+>W0N9?9[FG5U=C7.+FG?7E,YG\O?7_`()>EY%&'GX]F+D,9D46 M2RZIP#FF/S'M5/!^K'U?Z=D#*P,"G%O:"T65-VF#R/;]))3G=4^HV#U=@JZE MU#J&30/\`Z\"N1PYU;*VM>[^NMKIW3\;IF!CX&*"W'Q:Q76"9,-_>/[RMI)* M:6=TO"SC6_(KFVDS7:W1S?+=^X[]Q41]5>F':+S9>QI:0QY`$M'I@NV-;N_1 M[:W?\76MI)/CDG$4)$4Q3P8IGBE`$L:ZV5,;76T,8T0UK1``'9H"DG23&5__ MTO54DDDE-'K8_P`C9\ZC[-=_Y[>N7_Q;Y%^%@8_0I=/>1&['R6M? M?3I^=AYS[&>]W\S=2NIZW_R-G_\`A:[_`,]O7,'&NK^IWU?Z]AL+\[HF'CY+ M6")LQS16SJ.+[O\`38OOK]O\_34DI%]7NMY'3_JG]7NG=.QVY?5.HTN&-4]Q M94UMO^N>5@=.ZC9U+!#.H=&?1]MHKL)K?3>Y MM;,["N=7^DK_`)QWI/;^C]+TK7KEL/#HKZ;]5NIYV3DX/3GX+\.[-Q+74>C8 M^QMN,F=7'UAQNG7YF=3=C#I[.JYEYR:K M'EM[G,PW6`.HVSTW_`.#_`-)QM.'8RTOMJLL:;,:C.I=6 MWWY<;6.I_F;/T=ZP\[I^;7T7K?U$EUEM5'VSH;G`.-N(U]=WV-NR7.R,:ZIV M-^D]]GJ5V>GZ*A4?JWG7](;B=1ZKU;)RLBJQW3;,QUAQA4X6VW]1HL]1E/V. MP-]EG\]_VGWI*;/0.MGI&/UWT:#EYN9]9,O&P\5IV[['>D[WV0[TJ:F,?9=; MM]BW^F=?ZC]NR.D];Q&4=1Q\<9E?V1SKJ\BF=ECL?H])KQND9MU=.P6N.70V]S:L>_*I]/TONZ9TS*_:^3UOJEF1BWV7676/KQ!ZU7VO(NQ6[WU/TM?I? MOK1ZCU#I.)D=6ZCTG.OZ)]8,?)L8_I$^K7F7;]F/9^S'MW7NZG7Z7ZQB_P`Q MZWK?\+8E/4=1Z[U:SJMO2>@8E.7D83&6Y]N1::JZ_5EV/BL]-MEK\F^MKK=^ MST*6;/\`2+0Z'U9O5^FUYHK./82ZN_'<9=5=6YU.10\C_1VL=[OSV>]<;E4X M=/UBS[?K%U#+Z"_J%6/E8[L?+?10_P!.BK&SB]FR^MMK)G:]H<)\8^UJ^ M64DE/U,S'QZ]^RIC?5.ZS:T#<3^<^/I)G8V.ZYM[JF.N8(;:6@N`U^B_Z7YR M^6DDE/U-=CX][`R^MEK`=P:]H<)_>ARG`^]?*R22GZJ27RJDDI__V0`X0DE- M!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O M`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`#4` M```!`#A"24T$!@``````!P`(`0$``0$`_^$-QVAT='`Z+R]N&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!# M96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O7!E M+U)E&UP.D-R96%T;W)4;V]L/2)086EN M="Y.150@=C4N,#`B('AM<#I#&UP.DUE=&%D871A1&%T93TB,C`Q,2TP-"TR.%0Q,3HR,#HQ M,"TP-#HP,"(@>&UP34TZ1&]C=6UE;G1)1#TB0T%&,D0Y,3=&14,R-#A"0S!$ M1C1%13=",#4W.#8Y-34B('AM<$U-.DEN&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@&UP+FEI9#HP,3@P,3$W-#`W M,C`V.#$Q04-!1D1!1$,S-S%!1$-#0R(@&UP34TZ2&ES=&]R M>3X@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO'0`````0V]P>7)I9VAT(#$Y.3D@061O8F4@4WES=&5M```!`P0#`0``````````````!@@*`P4'"0$""P0!`0``!P$!```````` M```````!`@,$!08(!PD0```&`P`!`P0!`P4```````$%!@<("0(#!`H`0!$0 M(#$28"$R$T(C,Q06$0``!@$"!`,$!`H&"P$````!`@,$!08'$0@`(1(3,10) M42(C%4%A<180((&A,D(S0R070/#A4F(8L<'1\5-C@V0EM48*$@`!`@0$!`,& M!`<````````!$0(`(3$#01($!4!1(A-A,@;P<8&Q4B-@H=$DP>%"@C-#%?_: M``P#`0$"$0,1````G\`````````````=4>DRK+``L9B(!2BQ,8EY%>(,N1=# MYCL*4MI:3[A=E$MDUA]]M>?57G`$8>3&3O3SOSU(R,N.].Q%#)2)%!)3A%I) M"PXPU/&V8EX4X:RN@N?=1O1',KC]6W^0_P`3]J7BE=53@\J(])\U'$&HFH$( M0D6FG(D]&BDDB$*XV1DD MV;CM&CYPP6S+FPS=2HJH@'RG8KG(`!T*9W.Y\HR`SH9V`X.#DY``.A%0'9&Q MD1PLS(AKZ-S1#M-CAFD3AD$>4,Y$0/7+4/L.#D``T%FA(?N92-"!L\,N$N`A M+#B#"9F$;N9[$^743(](DSG0[@!U-<0U06A]!A,QJ8V)/9K[,9&MT?\`C.A0 M%I,<#DQ?&[$1&G3-:-`E%D4[>7;HV#D'Q[(->>'HI.-:60/`9 M'9T[=RX<`C1J=-33)1F^`_[ M_LAQUCOT[C#7U9+A1:]!@:&9H.7P&L1#]_YQ_]H`"`$#``$%`/:!\CZ#$`'V MW1W<.&T1T;[F,-`!\9^RVY_X^8[X]QFH M0*MH"'=EK],QEG_X7$1'7[+]]&`N:CC-/G&W:./(E4@;*4R39&">(_\`5[+: M&O8/=R`Y88?@/YQ_]H`"`$!``$%`/:?CU\C]AZ?DB9* MM4\$E([FO:I7P9A%FFY9I/FX0D2P(@GWM9 MI7&G4Z;:<'8+P--@.3O-1B!*J4XI><[<)"IKJS>)IL/16Y+>GW;ZSV?TV&?% MS[->S#;C]5^@D>Z"/OWCHUL6K4UM2]70H*YV]7$QJ>)?Q)D[%2WF&6N)\0JN M-E`"`B%8;!:'L472B)CC#*6!,F4^=<2B(IW38.&;[>!8N M0X!*Q+6XGZM*N/$Y`-E1 M30JHY0M^-J$TS&X2?%L\:VMB1XYOC*NG*UH5;XWCUO1*;NXLR[7Q.*4ZG+D: M9)HYSZS56%15LKT[>XQB*(C]#@X*2`N\C-Q$"Z-PKBRQCBBJTZC)3M))F`]_ M]):;L4:N%O.KVJ\:^I^PQC;4X5-%7NW)EY+7D&N^WSC7'1V=MN'H9KS/%NEN MEIO%%7Z'+:EV&YY,*R*]`![X@,F\L6FX2Z7K;LQ::J*I4\+>^E2KXW[DTER)&D!H2E9Z M7]\.(]=YDBFZ0S?%H8B'K]P`?KGUZ<,MO1JTX`("'V9YAKQ#HU98:]F.S$1# M$-G1I`7GK7@K(Y?,)&MEHQ)3Z#B`^OTQ]```'V;/[?(6DG+Z-\N+LI7])S0S M-6Q&+D`DHTUJ4)7IC1(.QR&,6&:>>8TRZOOK.;M\IK.FNB2X*1-X5>47'O=^;D7&(C/$V[2"DPWL=[R`:T6 M0>>5-@45H:LM"VQF*L]R;U\?;8)R\O;=_8V7G$#Z]I`NU+$B\@:-D=)QR3G8 MY^MP[&(&-YP=EX+WIB412Q#6Z,L-FJH"*5MS@5-0"6Z7XZSX@'-AV512:2$A MFDDY3I(.QM.UY(+G*X+5/R1=.P)Z+%R+G>FJ=FGP>E3*.VV+J8L>=2WOUE^? MKE\?$C(6JYZ[`+P:?]-LS&3@@5)Q2R1K\@1)MKG[AI3(:1DL=@50?KB]!\QK M`N#E$U7/IVZ>>JF%RIKY@CU5SFZ9L9RJYM[:9DQJYQ24@^NN*UR)O6Y%*3FM MM$LTK"LMDG)@LK)N7C^A70I_7+5-G"B!,RN:7OK+\^Y__]H`"`$"`@8_`.$" MPA,N')J.?L8=U8?IPN43M+3X\ZPW=]Q&7;&$HV1#BU05RW;;@%1$%5P!79?3 M&S;4WMWR_N@/>V3&9P07..(GEO3+FV+NF:'=+;A[C@H(=W+C`$( M.8Y25%540;.K8FHMD@TD0?`H?SA0*<&;I'W@DOC3E2/0.W[4W]_K+5W$F=LY MG$Y@YJ!I+D!:J9151N.X;GJQ_P`LN:UCBS+WB'%I'2,[!;N#+,=:E$G&U7GO M=O:X6!,D@N)FK&Y6DT MNDNW'-F#_D+LWDF1F<"55!RQU7J%VJ_>W6HQF5XZP!('MO:3/%J24RG&IWF\ MG<>\F5)A$HV@"3$ZUBYRX-MTOZ[50GU"7M.+&KMW#:?;*@C*3,)\/XP^ZW49 MD`09;?-*Y*^^L6]9K27W@#TDM"+*1``%%0"`VR*GVK#6),_CG__:``@!`P(& M/P#A*P7$\.&FY/\`N_2`X.5OQX60ZW8^[PI%_8=M4!,*CW)%G2;@[N[9AHEB"VT]^,@LZ1I]5HW+8 MN-45$DEY@#^0A_TE.#=`,K&Y2/J)'U#++YUC:+MT]5PW2*4[K^4%3U)P= MAP\4K&IW!H#MOU5W/5@F$RL\[G*I50&@R&$;A>:S[MQS"#X!`9&2M1,*K%G; MM)IEKVY0UN) M7\<__]H`"`$!`08_`/Z)J'/CD7F/U_B/9RR2\;`0C!+NOYB8?M8N+8(<@%9[ M)/%V[5FB`CIUJJ)@`FX**>X?!QRG)UE$,L4+HY:^5>OR MR::Z@HH+*QTO*M7*2+DR>B1SDT4^@>/F;BR02$;\L4FP?JRT>FS&'1`15F.\ M+@"_*_\`N->U]?MZ@SCB#IZ.OJ_F72P)V]?VG.;#EP2#J>6<:V>;.7K+#5V] M5>,G(AJ*3QHL^!PS7 MU_44`H\>]D_'I1'ETFNE;$?_`&GCP8QLF4`"@'O":XP`GVV'5`!1>QS]`5$5.T";E+I.GQZVV\F#Q+"WB];3< MN4J#VMQ%S*[L-WBY87PNU?U#$(V?"DBGC]K-S*E?9#931B_M5AT=L.>\+7['K0MSPOYF@.[-6[0X%@M"RR-97CH]T+9\ M5%=,SA+70IPUU/RP5NY=S5GJ&ZJ'W'VK;_N#O-0M-EA&&;89+'T;9:'D"QP3 M6:4BF]O!H11K(N&J:7F00`ZH^^(\2V5,^05GRU?LC93R75)BQ7&\V]T_AH." M>MX6/C*LJUL10B$6Z9U%P.GVE0<&`/HXQWMD?77(-TQ-&[TEL:.JM9;S:7#6 M8I,?=7$8,7+F^=!YI`\4D*:P@I\373C:KNWV!Y4R/@\E\N5CI-QQBTOUGL., M)62@F<5,1BGW(L;R;B6L?))*JH2"1.V"B(%_>YQNXJ^YEK-9GA*MC MNDO*TSN-MN#@D*]D9Q^G(NX_R\RR,Q,?;_=@&4+](U_;+>Z? M+;L]K2^0++>A@\9W71M-VR#82#Q>23(WJKM1\K'K)Z@DAWR:]`:1$_'+=Z-F MXN/EF"Y3`IWF7C[JO".*<2E:+Y)DX\KN,JY#%:G5)!U#R:5SFF,:XOTK/,"0M?1:-%D6 MR@NHH'RG;1(IVDD/B?1Q6(#+\D]N&.9V(@I)XPGG/F[=5X68,3Y;.HRQ7!5U M4&Z.BKIFX1%7RQBGY?2QF(MVA(1LDW3?1[UN<#H.&CD@*HJIJ!2-QU"'/ MZ/\`7^#4?#C,I3``=JHX,*'/^]6F0#IX_04.)(1_1_RH//#GS_E2MS^@.?&U MVGR+2+K^=Z/MBQ'.X2R;B9`151<-C]`: M)G'7UC(ZP9+@8_;WNKS#M^2HV5$I-B,6C,SFV'!R5/$BAOX<9N%O`HLEV:OQ M?-$\O^OQ*6!@EES&C-B\1;0N?<-RLX%#N,4DJ4D>\EY6&`C=GJB.JS1^EJD4 MIB>^GH!\-[:M]]6J=YS*_9SE3V^[G8B#8LK8UD;`P0>3-*MB;-N5$[6Q)1;< M/.LD4DE%4T"."#S.ED:948N9!.*6V]RBL>S.BF[?I-BH.@8-`7T016<=@4Q% M3GW%.7/B@;4<'[2I/;]BMS9:Q?,BY.S5DZAH(3J$2D",3!1T'4I6P2YT$"/5 M'2JH))K*=)"))ZAQL=VZ1]G^^]UG]REUR'E>[)M31S*?O4M1VK/R\0U`2+I5 MV&BF96;5-7XBX@7E?$!'G8&1@Y@'L'AC:H&GR^0YN)WZ M6=Q$4F$DHR(D[)(!>GZ+*)9R4PL@P9.'3@N@=Q1%'GS]O&(=CFXD6WIP8TP= M4,44QP\J4UDYKCQ1@DE(OEVIHPKN-?C.N'+@%A\MW&HCTZ]SW^/4 MNS-NFKOR7,]XW%4R-R!4'T0HQ:5C[O4R7@F=*&(D`[R+*#BD4VXI*=T%/TNX MIU:CV8PS3R37N,TR,3I>7;`RU1,V1*@`E0\JJB9/H#]F)/`.-Q]FN;QX2M4% MSDB^74C%95*2>1%.FD*[6ZQ'K*D.5JM(G<(-^X`AVD@5[>O%)I+>(:6"[R4` MVR@GCTQDXG%F**Q)-?/L9*W&*GYJ>FFD8"*[MP^[22:0D3]_J$G%U52=H9%R M)>6+ZO2M^=H&^[4)"+J=IZVIL8J0IEEW:3VPXHSC]YBGL,X2' M*@]\R[E7+]4C=)NFEW05^'V^-K4WCNWP4S*0&$J#4+35V4PT>6&K3](@F=5E MFT[&(KC(QRIGD;W0[B6G:4)PMG'"A3: MR6G?D-$3?*EU1T;J&[8^X8-/4R3F$)NH9#QGO3KBR4>_;G:3L#=ZE,8<4BV# MIFMY19F\;3#,B8)*B&@::^WBKSMG2JLMDB)KD;4-Q&(+0UCW[J)N#1@T2D'; MVM2Z)P>5V<+T.VRX)JI'%8Z>O<(/,;24 M5%JS4K2V4^D?Y(R6):CF:BT[FJ:0\_AH<9JOF.+5#7BJQ`8JCEYRO/BOX=S+ M5J*:NYA@RD&B;F+>%;AJFLJDMKW2@'LXQY?<86VNW2L3%+J;M"2K,VPGVB`N MX&->"T>*QSEQV'[;O?%35T5UXV<4EG.1+JU,LJ72>?P2$@U=2<=#)5=!IYY] M&-W02*23MZY(D@H=(=%A,.@@'$5&O;?6V3RKYMRXM8FCR68-5X%NK(M9=NXE MD%7`_+6J\647")U1_8EYB`AQ0LDJVB&;T%SZ@PS8VMT\;D@/D+K)ASI2J\GI M\O%B!5B*]SN]K\_&+O4FQ-&HR3!52+Q5G)_`F;NFYV[GK_ES?%5VVK;LH.R_ M+5G.HCW?*)AJ(\;N=NV8\@,TL_8*@\>8FK[2P3*)I_(-6>9%J+VA/85N^<%> M3+^(C(QRS=`.@`#0#J:<^-XC*6G(A@]F,84$T,S?OVS=[+`TF!<.U8I-9QWG MY6P+BHJ*0!VO9RU'>'N&BT*W9^'UJ'XVRSF2).1FS$:MYUW)-T"] M!4#/6*,FU.813\TD?^]SOQ&BJ;J6R'@IGBE9ZQ*8_F;+CU:+LD'\M?%T,,'F MG&T,=PTYB*KI@LA^F3HXBZ70&3UTT>.6_P`ZGACU482J0H&2+)R#N1%L=J+W ML]8M6QM%14+H'%;)M8BNQR3%HF0H)=8Z]QTY,0!'X[IVJ=173D*AQ\-> M!U#GIR\/;^"6IEXKD5;*I/-@9S5=G&:4A$2S3O)+^6?,W6K9TAYA$@]"@?J\ M"([-MMRAA'K,93$5)44,IR]_5:&\>&\"\VI8(`&\.+]#2V'J.[A\J9#@\K9%B%H%C\NN>0ZZK&K1MLL;,![$O.-QA&@ M=]7N:^72Y>YPXR'+[>:)$WIXVWQ,897.,,UTBWQ:3R(LF.Y&1^2(W>-:JN.XB^ M0KTDVE8Y41#44P)I[Y^*[D[#&V#!;J,EHAI)URWT8JA@>1,NP2>(JHR,3(C\ M%RQ>$'MJ\]#\+2DYLTQ#/2:VGD`,.GN@)M`,;ZBZCJ'#W*F:MLF*LAW^4:,VNH<^'=%P918C'E0=OQDAKT&5=.-1="7HU;-W"ZY&Z?2/Z)`*'X M>8<>'YQ_V\:`&@?BZZ"//EH&IN?+W=>6HZZ:CH`!S'EQZ45CVDV&ZN',&GOE MSCE/#D#:Y"%J^:\<;:*AM^RS>:Y;X)!VG'VDS#&+6RC'HJ-U723AT868@X,E MQN!W9;4LHVZI*VO'&VS(>*\F4&PR=5N$?!W_`#SA($EH^;@'9)*+?OZ].K,G MR*:PJ`"J[=8H@90@U:R[B+C+L9"^S@5O&V.Z-5IJ_90R--IIIJOF5-H59;O) M^7)#-U"*/'`I)-&PK(I"IYA5%)3+.[&E90EE,5X!CI61SXPDJ!>FF2,*!`,% M)2<:Y&Q@C`N+I"*P\8@L[54*S6;>5;KKD6,DBH.?1E8JE)J)BOG\E(K-&"2)BZ+ M:B`#1,*4_(N1H&>RY9R4W"UKR'AK(=&QMF>R.)#Y9'Q..+S-0K:(E'4N_,@W M:%<>4.NX=MD`#S"R:(F!,1,`G'GTF_5.&H@)P`>G4!`HAK]0:!IQA/=MECU0 M_5-J]_RA+YL;S4!C_==(Q=19%H&?,H8T@4XEE8*U-R38BT13FQSBJY6`RRAC MAJ0Q0#=YZ9&9]PF0]UE$QGA[$.YK`&7ZS>WBA7<7!F9ZE; M>VFCTG/.'KAB*1R)"PS5_(SB]#7L3(6-@/"QT0Y M=K$*H111LBLJW[R;=R=&ZX=O&3\@B;&5K=T/*65:UAW(EKPCC>\QRZ[*2J%M MR)`PC]@WFHE^0C5R5JFZ21/(EADK& M%[IUBQWE3':UB1>N*XI<:+9V3*28L[`RC%5F;I/O(*D()0.!BG(7C\P^W3ZA M_%]!)H]137:NJUZM39=!=)-=!PDOMEA9ODK$K9VN/<$,L*UG,,T^NUEN4<\R#&O$ M9^P7">8.X_O1QT%VS$IDW'47R_;WUY+W*[$VFQW`F]#T^9;`^7*XEGG"^?8_ M)&?(2TEJM'OLI&T]W%@,DGAV\3K$!>Q"J'_C@,H\$52HCZ;NRR20-,W_`&?; M,O5#OV7*FL4"<(T;PLBLHW3-*K'(FT3:E#H M,@C;11C<2>@U5<9ZA5+(XN"\E(-(]S'MW\?CZ$%O(G2:Q,V M(-U`32<-#$,&S79YZXGIZ2F%Z!@*_80KV!MWE(G4;WM))E##[%*KXEOMCMM- MEV4OAZ??-T'#D22)E6X@*RKA)NB"Q&PF0`X$`P`4IP,F/PS`4=`U-TE'ITTT M#4P&Z@YCIB#)VS7U1*_@NF.U]QKG%VVZR[4,47&"B)>!W*9BB9F,DLQ6`)JU MK-KA:HE])G<*Q;H&OS'L)D[*1=/5DWQ1UCS#(^IO!XGW.US>#;,\24`_ROCC M->W'#%M?T&@U4*+'5RNUW%%1("*T&2.:-!7$AR&5$K1(J6)]G%#]#:.REMZR MWM98L4\IOM[VW6$5R6TS963W)SFEU4)FL&>PLY-2]M^>L&K\3240N"*)U>\V M!3C_`/*U0-S46I#;@,7[;_55IEXC'DS"6M=J\H>T^@05<"1G*U-2T//2!ZQ% M,5%W+5Z<+9O(P)4QW!VC)=\M43> M%[50+O7W\ZE&I&B30AFDJLN59NTZQ*=)8`#:)@OU'MG-FSCGZM[R9M'8ULPK M%N@9AL;0[+-4/FW-KY].8OD'-HC+%/U*+CJM7ZB=.I(O_`"R/ M:.N+EB`@(M5^K=3L]WJ[!;+NF],C)V2]PUZD=U6WAY'V^QQF,,VV:7FK,MGS M%;-]$W&$DJ?&2"2;^;:.(H8U-D*K-5D;'YFVMX MLBLX5'#5/HD%E3+]GP?+9-9V#++*73<2T'0JC"0*D4H5":;.%4U'!^ZT.F-' MWE9C].TFR+&LOM9O&!,[R++WCT MZMXL55TSEV5P(>93 M5*FGS)QCNITZ\5_$V:L5W1>6K&0)]C+O(=[2;$W;IWRBS3.OJIR%<,T^0))U_'^-8BS,6=GFW9I85'9Y25`SE$QCE)UJN7SMWO2WFVO(E`R-B MO>!C.T59C@[=7@57$>]3`%B3L"S#*-LKK,T70\K M5U%LLK!L[0UK3,JRM"MB8PN*T;&2SJ*82<@NR=^1O"TK8K]DQAGW"-3Q1"2I;&"*#!"1C92O*R9`#`#^E0,S3 M[%7FTRY7EX-C/H]EDYZ$C$,H9R[7V+T39'N!CHG=7Z>V3+)F+&&5-PT?)6FE M96M^2HJD*M7K22:[4<#-&36AF*";8AEE!4>#LUWC;S]T6VQ2 M[[4,YQ5KA-MF`:-D.-V^Q6-9:'-'Y0E8NUV^1'(=GS);3),Q;.I5$D6R19]H MA`*L/1F+9?M0W9[29'8]E.PY$^YM_P!PD!EF=W78!H>9K!8)O(=9I:%:8_<" MUR;->ROE6;R5?J=UXX%9,D>``D38_9O3MRU!XHW3>GQC.3Q#BRPYJ;2%DQCG M;&5PBT&^0J/GN-KS-W+((6*P`I.LWD.10(6175%HVZA:*,;EZ@_J-YGQ?>]P MCO&26"<28;VS_?.%VWX9Q<:0;SD[)1Z-[12MMWN=HGT!